Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
18
SMTI Quote, Financials, Valuation and Earnings
Last price:
$18.92
Seasonality move
:
27.14%
Day range:
$18.85 - $20.00
52-week range:
$18.85 - $36.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.59x
P/B ratio:
27.48x
Volume:
100.9K
Avg. volume:
61.4K
1-year change:
-46.35%
Market cap:
$169M
Revenue:
$86.7M
EPS (TTM):
-$4.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
$27.2M | -- | 17.99% | -- | $40.00 |
|
ATR
AptarGroup, Inc.
|
$995.3M | $1.40 | 7.1% | -0.86% | $161.43 |
|
DXR
Daxor Corp.
|
-- | -- | -- | -- | $22.50 |
|
POCI
Precision Optics Corp., Inc.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
|
WRBY
Warby Parker, Inc.
|
$213.1M | $0.05 | 13.12% | 437.89% | $27.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
$18.91 | $40.00 | $169M | -- | $0.00 | 0% | 1.59x |
|
ATR
AptarGroup, Inc.
|
$142.58 | $161.43 | $9.2B | 24.23x | $0.48 | 1.31% | 2.52x |
|
DXR
Daxor Corp.
|
$12.40 | $22.50 | $72.3M | 40.36x | $0.00 | 0% | 57.50x |
|
POCI
Precision Optics Corp., Inc.
|
$4.76 | -- | $36.7M | -- | $0.00 | 0% | 1.58x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.28 | $5.50 | $37.8M | -- | $0.00 | 0% | 4.41x |
|
WRBY
Warby Parker, Inc.
|
$22.46 | $27.25 | $2.7B | 5,910.53x | $0.00 | 0% | 3.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
88.52% | 0.330 | 16.72% | 1.64x |
|
ATR
AptarGroup, Inc.
|
36.73% | -0.029 | 19.66% | 1.07x |
|
DXR
Daxor Corp.
|
2% | 1.361 | -- | 0.09x |
|
POCI
Precision Optics Corp., Inc.
|
29.28% | 0.927 | 13.48% | 0.74x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
|
WRBY
Warby Parker, Inc.
|
38.62% | 3.403 | 6.9% | 2.13x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
$23.8M | $3M | -8.95% | -20.48% | 11.25% | $1.1M |
|
ATR
AptarGroup, Inc.
|
$261.6M | $110.3M | 10.13% | 14.78% | 11.46% | $96.2M |
|
DXR
Daxor Corp.
|
-- | -- | 1.52% | 1.57% | -- | -- |
|
POCI
Precision Optics Corp., Inc.
|
$946.4K | -$1.6M | -43.33% | -54.55% | -23.88% | -$226.6K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
WRBY
Warby Parker, Inc.
|
$115.6M | $3.6M | 0.13% | 0.2% | 1.62% | -$1.5M |
Sanara MedTech, Inc. vs. Competitors
-
Which has Higher Returns SMTI or ATR?
AptarGroup, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of 7.72%. Sanara MedTech, Inc.'s return on equity of -20.48% beat AptarGroup, Inc.'s return on equity of 14.78%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M ATRAptarGroup, Inc.27.18% $1.13 $4.3B -
What do Analysts Say About SMTI or ATR?
Sanara MedTech, Inc. has a consensus price target of $40.00, signalling upside risk potential of 111.53%. On the other hand AptarGroup, Inc. has an analysts' consensus of $161.43 which suggests that it could grow by 13.22%. Given that Sanara MedTech, Inc. has higher upside potential than AptarGroup, Inc., analysts believe Sanara MedTech, Inc. is more attractive than AptarGroup, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 ATRAptarGroup, Inc.3 3 0 -
Is SMTI or ATR More Risky?
Sanara MedTech, Inc. has a beta of 1.009, which suggesting that the stock is 0.90300000000001% more volatile than S&P 500. In comparison AptarGroup, Inc. has a beta of 0.483, suggesting its less volatile than the S&P 500 by 51.651%.
-
Which is a Better Dividend Stock SMTI or ATR?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AptarGroup, Inc. offers a yield of 1.31% to investors and pays a quarterly dividend of $0.48 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. AptarGroup, Inc. pays out 31.11% of its earnings as a dividend. AptarGroup, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMTI or ATR?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are smaller than AptarGroup, Inc. quarterly revenues of $962.7M. Sanara MedTech, Inc.'s net income of $834.5K is lower than AptarGroup, Inc.'s net income of $74.3M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while AptarGroup, Inc.'s PE ratio is 24.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.59x versus 2.52x for AptarGroup, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.1.59x -- $26.3M $834.5K ATRAptarGroup, Inc.2.52x 24.23x $962.7M $74.3M
-
Which has Higher Returns SMTI or DXR?
Daxor Corp. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of --. Sanara MedTech, Inc.'s return on equity of -20.48% beat Daxor Corp.'s return on equity of 1.57%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M DXRDaxor Corp.-- -- $36.5M -
What do Analysts Say About SMTI or DXR?
Sanara MedTech, Inc. has a consensus price target of $40.00, signalling upside risk potential of 111.53%. On the other hand Daxor Corp. has an analysts' consensus of $22.50 which suggests that it could grow by 81.45%. Given that Sanara MedTech, Inc. has higher upside potential than Daxor Corp., analysts believe Sanara MedTech, Inc. is more attractive than Daxor Corp..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 DXRDaxor Corp.1 0 0 -
Is SMTI or DXR More Risky?
Sanara MedTech, Inc. has a beta of 1.009, which suggesting that the stock is 0.90300000000001% more volatile than S&P 500. In comparison Daxor Corp. has a beta of 0.011, suggesting its less volatile than the S&P 500 by 98.935%.
-
Which is a Better Dividend Stock SMTI or DXR?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Daxor Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or DXR?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Daxor Corp. quarterly revenues of --. Sanara MedTech, Inc.'s net income of $834.5K is higher than Daxor Corp.'s net income of --. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Daxor Corp.'s PE ratio is 40.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.59x versus 57.50x for Daxor Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.1.59x -- $26.3M $834.5K DXRDaxor Corp.57.50x 40.36x -- --
-
Which has Higher Returns SMTI or POCI?
Precision Optics Corp., Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of -24.5%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Precision Optics Corp., Inc.'s return on equity of -54.55%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M POCIPrecision Optics Corp., Inc.14.17% -$0.21 $15.4M -
What do Analysts Say About SMTI or POCI?
Sanara MedTech, Inc. has a consensus price target of $40.00, signalling upside risk potential of 111.53%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sanara MedTech, Inc. has higher upside potential than Precision Optics Corp., Inc., analysts believe Sanara MedTech, Inc. is more attractive than Precision Optics Corp., Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 POCIPrecision Optics Corp., Inc.0 0 0 -
Is SMTI or POCI More Risky?
Sanara MedTech, Inc. has a beta of 1.009, which suggesting that the stock is 0.90300000000001% more volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock SMTI or POCI?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or POCI?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Precision Optics Corp., Inc. quarterly revenues of $6.7M. Sanara MedTech, Inc.'s net income of $834.5K is higher than Precision Optics Corp., Inc.'s net income of -$1.6M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.59x versus 1.58x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.1.59x -- $26.3M $834.5K POCIPrecision Optics Corp., Inc.1.58x -- $6.7M -$1.6M
-
Which has Higher Returns SMTI or PSTV?
Plus Therapeutics, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of -316.61%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About SMTI or PSTV?
Sanara MedTech, Inc. has a consensus price target of $40.00, signalling upside risk potential of 111.53%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1898.55%. Given that Plus Therapeutics, Inc. has higher upside potential than Sanara MedTech, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Sanara MedTech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is SMTI or PSTV More Risky?
Sanara MedTech, Inc. has a beta of 1.009, which suggesting that the stock is 0.90300000000001% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock SMTI or PSTV?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or PSTV?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Sanara MedTech, Inc.'s net income of $834.5K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.59x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.1.59x -- $26.3M $834.5K PSTVPlus Therapeutics, Inc.4.41x -- $1.4M -$4.4M
-
Which has Higher Returns SMTI or WRBY?
Warby Parker, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of 2.65%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Warby Parker, Inc.'s return on equity of 0.2%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M WRBYWarby Parker, Inc.52.13% $0.05 $602.2M -
What do Analysts Say About SMTI or WRBY?
Sanara MedTech, Inc. has a consensus price target of $40.00, signalling upside risk potential of 111.53%. On the other hand Warby Parker, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 21.33%. Given that Sanara MedTech, Inc. has higher upside potential than Warby Parker, Inc., analysts believe Sanara MedTech, Inc. is more attractive than Warby Parker, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 WRBYWarby Parker, Inc.7 4 0 -
Is SMTI or WRBY More Risky?
Sanara MedTech, Inc. has a beta of 1.009, which suggesting that the stock is 0.90300000000001% more volatile than S&P 500. In comparison Warby Parker, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SMTI or WRBY?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Warby Parker, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or WRBY?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are smaller than Warby Parker, Inc. quarterly revenues of $221.7M. Sanara MedTech, Inc.'s net income of $834.5K is lower than Warby Parker, Inc.'s net income of $5.9M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Warby Parker, Inc.'s PE ratio is 5,910.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 1.59x versus 3.26x for Warby Parker, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.1.59x -- $26.3M $834.5K WRBYWarby Parker, Inc.3.26x 5,910.53x $221.7M $5.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
